









Markets
/
Stocks
/
nasdaq-prta
/

Prothena Corporation PLC

PRTA

10.560USD

+0.480+4.76%

Close 11/07, 16:00（ET）Quotes delayed by 15 min

568.44MMarket Cap

LossP/E TTM



Prothena Corporation PLC

10.560

+0.480+4.76%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Prothena Corporation PLC

Currency: USD Updated: 2025-11-07

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Prothena Corporation PLC's Score

Industry at a Glance

Industry Ranking

75 / 407

Overall Ranking

194 / 4614

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 7 analysts

Hold

Current Rating

18.333

Target Price

+73.61%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Prothena Corporation PLC Highlights

StrengthsRisks

Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 150.73% year-on-year.

Overvalued

The company’s latest PE is -2.03, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 41.66M shares, decreasing 25.62% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 3.67K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-07

The company's current financial score is 7.48, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 4.42M, representing a year-over-year decrease of 96.65%, while its net profit experienced a year-over-year decrease of 288.03%.

Score

Industry at a Glance

Previous score

7.48

Change



Financials

9.89

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.19

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.81

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.51

Key Metrics

Free cash flow

No Data

Prothena Corporation PLC's Company Valuation

Currency: USD Updated: 2025-11-07

The company’s current valuation score is 7.12, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -2.03, which is -46.79% below the recent high of -1.08 and -1833.43% above the recent low of -39.18.

Score

Industry at a Glance

Previous score

7.12

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 75/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-07

The company’s current earnings forecast score is 6.86, which is lower than the Biotechnology & Medical Research industry's average of 8.00. The average price target for Prothena Corporation PLC is 14.50, with a high of 36.00 and a low of 4.00.

Score

Industry at a Glance

Previous score

6.86

Change

Support & Resistance

No Data

Analyst Rating

Based on 7 analysts

Hold

Current Rating

18.333

Target Price

+73.61%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Prothena Corporation PLC

PRTA

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-07

The company’s current price momentum score is 6.15, which is lower than the Biotechnology & Medical Research industry's average of 6.46. Sideways: Currently, the stock price is trading between the resistance level at 11.63 and the support level at 9.55, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.84

Change

0.31

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.110

Neutral

RSI(14)

58.010

Neutral

STOCH(KDJ)(9,3,3)

31.253

Neutral

ATR(14)

0.583

High Vlolatility

CCI(14)

19.554

Neutral

Williams %R

57.071

Sell

TRIX(12,20)

0.346

Sell

StochRSI(14)

86.329

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

10.342

Buy

MA10

10.450

Buy

MA20

10.284

Buy

MA50

9.489

Buy

MA100

8.261

Buy

MA200

9.499

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-07

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.16. The latest institutional shareholding proportion is 77.40%, representing a quarter-over-quarter decrease of 18.83%. The largest institutional shareholder is The Vanguard, holding a total of 2.17M shares, representing 4.03% of shares outstanding, with 55.30% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

7.90M

-0.51%

Scully (William P)

5.35M

-4.56%

Fennell (Todd W.)

4.35M

-5.23%

Adar1 Capital Management LLC

3.38M

BlackRock Institutional Trust Company, N.A.

3.12M

-4.95%

Armistice Capital LLC

2.24M

+1.82%

The Vanguard Group, Inc.

Star Investors

2.17M

+71.95%

Palo Alto Investors LP

1.27M

-23.20%

Citadel Advisors LLC

1.15M

+1183.71%

Acadian Asset Management LLC

1.02M

Risk Assessment

Currency: USD Updated: 2025-11-07

The company’s current risk assessment score is 6.41, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is -0.09. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.